Our findings provide new insights into the sophisticated epigenetic mechanisms that EBV harnesses to drive tumor progression and suggest a promising therapeutic strategy targeting KDM5B and its molecular interactions for treating EBV-associated epithelial cancers. The gene discussed is KDM5B; the disease is neoplasm.